Antibe Therapeutics Receives Approval To Proceed To Phase 2 Clinical Trial

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) is pleased to announce that it has received approval from Health Canada to initiate a Phase 2 trial. Antibe submitted an application to Health Canada to perform a trial in which ATB-346, its lead drug, would be tested for effectiveness in patients with osteoarthritis of the knee. The study is expected to begin in March, and will be performed by Topstone Research, in Toronto. Antibe’s CEO, Daniel Legault, commented “We are delighted to move forward into patients. In the past year we have performed a number of non-clinical studies of this drug and these studies suggest that ATB-346 is a much more potent and long-lasting anti-inflammatory drug than we had anticipated.”

“We are delighted to move forward into patients. In the past year we have performed a number of non-clinical studies of this drug and these studies suggest that ATB-346 is a much more potent and long-lasting anti-inflammatory drug than we had anticipated.”

About Antibe Therapeutics Inc.

Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com.

Antibe’s subsidiary, Citagenix Inc. (Citagenix), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become the largest source of knowledge and experience in the Canadian medical device industry. Citagenix Inc. is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com.

Forward Looking Information

This news release includes certain forward-looking statements which may include, but are not limited to, the development of ATB-346 and other drugs and the addition of products to the company's product line. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, risks associated with drug development generally, and not obtaining future financing on adequate terms, or at all. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.